Date | Compound | Laboratory | Indication | Type of Information |
---|---|---|---|---|
2012-06-21 | hexasodium phytate | Sanifit Laboratoris (Spain - Switzerland) | calciphylaxis | Granting of the orphan status in the EU |
2012-06-21 | human apotransferrin | Sanquin Blood Supply Foundation (The Netherlands) | congenital hypotransferrinaemia | |
2012-06-21 | recombinant human pentraxin-2 | Appletree Europe (Luxembourg) | idiopathic pulmonary fibrosis |
Granting of a patent |
2012-06-21 | 1-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H- pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-3-(3-fluorophenyl)urea | Abbott Laboratories (USA) | ovarian cancer | |
2012-06-21 | adenovirus-associated vector containing human Fas-c gene | Gregory Fryer Associates (UK) | glioma | |
2012-06-21 | autologous CD34+ cells transfected with lentiviral vector containing the Wiskott-Aldrich syndrome protein gene | Fondazione Telethon (Italy) | Wiskott-Aldrich syndrome | |
2018-05-23 | autologous haematopoietic stem cells transduced with lentiviral vector Lenti-D encoding the human ABCD1 cDNA | bluebird bio France ( USA - MA) | cerebral adrenoleukodystrophy (CALD) | Granting of the Breakthrough Therapy status |
2012-06-21 | polyinosine-polycytidylic acid coupled with the polycationic polyethyleneimine | Bioncotech Therapeutics (Spain) | pancreatic cancer | |
2012-06-21 | BRCA MASTR™ Dx test | Multiplicom (Belgium) | identification of mutations in the coding regions of the BRCA 1&2 genes in individuals with increased risk for breast, ovarian and/or related cancers | |
2012-06-22 | VAC-3S immunotherapy | Innavirvax (France) | HIV/Aids | |
2012-06-24 | diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA),poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (adsorbed) combined bacterial and viral vaccine | Sanofi Pasteur (France) | primary and booster vaccination of infants and toddlers from six weeks to 24 months of age against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae type b |
Granting of a Market Authorisation in the EU |
2016-05-31 | ceftaroline fosamil | AstraZeneca (UK) Allergan (Ireland) | acute bacterial skin and skin structure infections (ABSSSI) community-acquired bacterial pneumonia (CABP) | Granting of a Market Authorisation in the US |
2012-06-24 | everolimus | Novartis (Switzerland) | hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor | Granting of a Market Authorisation in the EU |
2012-06-26 | velaglucerase alfa | Shire (UK - USA) | Gaucher disease |
Granting of a patent |
2013-11-15 | canagliflozin | J&J (USA) | type 2 diabetes |
Granting of a Market Authorisation in the EU |
2012-07-05 | CGEN-15022 | Compugen (Israel) | solid cancers and hematological malignancies | |
2012-07-06 | semuloparin sodium | Sanofi (France) | prophylaxis of venous thromboembolism (VTE) in cancer patients receiving chemotherapy for locally advanced or metastatic pancreatic or lung cancer or for locally advanced or metastatic solid tumors with a VTE risk score ? 3 |
Withdrawal of a market application in the US |
2012-07-09 | KRAS test - PCR companion diagnostic | Qiagen (The Netherlands - Germany) | guidance on the use of Erbitux® (cetuximab) as a treatment in patients with metastatic colorectal cancer |
Granting of a patent |
2016-04-21 | anakinra | Swedish Orphan Biovitrum (Sobi) (Sweden) | Cryopyrin-Associated Periodic Syndromes (CAPS): |
Granting of a patent |
2015-04-24 | eribulin | Eisai (Japan) | locally advanced or metastatic breast cancer |
Product launch |
© 2024 Biopharmanalyses - Powered by Samacom+